olverembatinib
ascentage pharma
['leusm', 'olverembatinib']
congress #eha2023 | kaibo lu, describes the use of of olverembatinib and pdt-all-2016 in ph+ve-all in china. n=13. all had a median follow-up of 8.97 months (range 6.42-11.51) and all enrolled achieved cr for an orr of 100%. median os was nr #leusm #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm